Global Minimal Residual Disease Testing Market Landscape: Trends and Market Share to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Minimal Residual Disease Testing Market Through 2029?
In recent years, the market size for minimal residual disease testing has witnessed a robust expansion. The market, which was valued $1.59 billion in 2024, is projected to reach $1.8 billion in 2025, registering a compound annual growth rate (CAGR) of 12.9%. The enhancement in cancer research, necessity for treatment monitoring, compelling clinical evidence, regulatory backing, and improved patient outcomes are factors that have contributed to the growth in this historical period.
Expectations are high for a swift expansion in the minimal residual disease testing market over the coming years. Predicted to balloon to a worth of $2.91 billion by 2029, with a compound annual growth rate (CAGR) of 12.8%. A multitude of factors will contribute to this rise during the forecast period, including a surge in cancer cases, advancements in therapy procedures, the growing trend of precision medicine, a shift towards early detection, and the integration of healthcare systems. Key trends for the forecast period will encompass the inclusion of liquid biopsy approaches, emphasis on early relapse detection, the broadening use of MRD testing in clinical trials, a rise in its adoption in pediatric oncology, and partnerships aimed at promoting research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
What Market Forces Are Driving The Minimal Residual Disease Testing Sector In 2025 And Beyond?
The rise in cancer cases is anticipated to fuel the expansion of the minimal residual disease testing market. Cancer is a disease characterized by uncontrolled cell growth and spread throughout the body. The primary method of detecting cancer stages is through minimal residual disease testing, an extremely precise procedure for locating cancer cells in the human body. It allows patients to halt the progression of cancer at a premature stage, thereby bolstering the minimal residual disease testing market. For example, the American Cancer Society Inc., a nonprofit organization based in the US, reported in 2022 that an estimated 1.9 million new cancer cases would be identified, resulting in approximately 609,360 cancer-related deaths in the US in 2022. Consequently, the escalating incidence of cancer is propelling the minimal residual disease testing market’s expansion.
How Is The Global Minimal Residual Disease Testing Market Categorized By Segments?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
What Long-Term Trends Are Likely To Affect The Minimal Residual Disease Testing Market?
In the minimal residual disease testing market, one key trend that is being observed is the innovation of products. To maintain market dominance, leading companies within this sector are introducing novel products. For an illustration, Twist Bioscience, a genomics and synthetic biology firm based in the US, in 2022, unveiled its Twist MRD Panel. This product was created to boost research and development in the detection of minimal residual disease (MRD) during cancer screenings. Essentially, the Twist MRD Panel is a specialized gene panel that can identify extremely low concentrations of remaining cancer cells in a patient’s bloodstream. Known for its versatility and customizability, the Twist MRD Panel can fit into any standard next-generation sequencing workflow and is capable of discovering minimal residual disease within a duration of only five days.
Which Firms Are Considered Leaders In The Minimal Residual Disease Testing Market Space?
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Minimal Residual Disease Testing Market Expansion?
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
